Bone Biologics Announces Closing of Registered Direct Offering at Market Prices Under Nasdaq Rules
BURLINGTON, Mass., November 20, 2023–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiology products for the spine fusion markets, today announced the closing of its previously announced registered direct offering at market-based prices under Nasdaq rules of an aggregate of 1,139,063 shares of its common stock at a purchase price of $0.64 per…
